Paclitaxel Initiation in Breast Cancer Treatment

Key Clinical Considerations

The National Comprehensive Cancer Network (NCCN) recommends paclitaxel as a preferred single-agent chemotherapy option for metastatic triple-negative breast cancer, with standard dosing of 80 mg/m² weekly or 175 mg/m² every 3 weeks, without mention of sodium level requirements 1, 3.
The primary safety monitoring for paclitaxel focuses on hematologic toxicity, peripheral neuropathy, and hypersensitivity reactions—not electrolyte abnormalities, as per the NCCN guidelines 1, 2.
Treatment decisions should be individualized based on previous therapies, pre-existing comorbidities, disease extent, toxicity profiles, and patient performance status, but sodium levels are not listed among these considerations, according to the NCCN 1, 3.

Severe hyponatremia can impair performance status, increase fall risk, cause confusion, and complicate assessment of chemotherapy-related toxicities, making correction prudent before starting any systemic therapy, as suggested by the NCCN 1.
For patients with recurrent triple-negative breast cancer who have received multiple prior lines including platinum and anthracyclines, paclitaxel remains a viable option with weekly dosing showing superior overall survival compared to every-3-week administration (HR 0.78; 95% CI 0.67-0.89), according to the NCCN 1, 3.

If sodium <130 mEq/L, the NCCN recommends delaying chemotherapy, investigating the underlying cause, correcting hyponatremia, and reassessing within 3-7 days before initiating treatment 1.
If sodium 130-134 mEq/L, consideration should be given to brief correction (24-48 hours) if symptomatic or if other comorbidities are present; asymptomatic patients may proceed with close monitoring, as per the NCCN 3.

For patients who have received ≥2 prior therapies for metastatic disease, the American Society of Clinical Oncology (ASCO) strongly recommends sacituzumab govitecan, with superior outcomes (ORR 35% vs 5%; median PFS 5.6 vs 1.7 months; HR 0.41) compared to standard chemotherapy 5, 6, 7.
If germline BRCA1/2 mutations are present, the European Society for Medical Oncology (ESMO) prefers PARP inhibitors (olaparib or talazoparib) over chemotherapy in previously treated patients 5, 6, 7.